148905-78-6

Basic information

• Product Name: Bexlosteride.
• Synonyms: Benzo[f]quinolin-3(2H)-one,8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, (4aR-trans)-; Bexlosteride; LY300502
• CAS NO: 148905-78-6
• Molecular Formula: C14H16ClNO
• Molecular Weight: 249.73594
• Mol File: 148905-78-6.mol

Chemical Properties

• Boiling Point: 413.9°Cat760mmHg
• Flash Point: 204.1°C
• Appearance: /
• Density: 1.202g/cm³
• Vapor Pressure: 4.65E-07mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: Bexlosteride.(CAS DataBase Reference)
• NIST Chemistry Reference: Bexlosteride.(148905-78-6)
• EPA Substance Registry System: Bexlosteride.(148905-78-6)

Safety Data

• Hazardous Substances Data: 148905-78-6(Hazardous Substances Data)

Usage

Uses

Treatment of prostate cancer (inhibits human type I isoform of 5 - reductase).

InChI:InChI=1/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1

Upstream product

• 146117-75-1 8-chloro-4-methyl-1,2,3,4,5,6-hexahydrobenzo[f]quinolin-3-one 
• 154097-61-7 (-)-(4AS)-(10BS)-8-chloro-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline-3-one 
• 74-88-4 methyl iodide 
• 148905-77-5 (+)-(4AR)-(10BR)-8-chloro-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one 
• 161320-16-7 ethyl 3-<(2-R-N-tert-butyloxycarbonylmethylamino-6-chloro-S-1,2,3,4-tetrahydronaphtalen)-1-yl>-propionate 
• 74-87-3 methylene chloride 
• 205105-67-5 trans-dl-8-chloro-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one 
• 17556-18-2 6-chloro-3,4-dihydro-1H-naphthalen-2-one 
• 148835-22-7 8-Chloro-4-((S)-1-phenyl-ethyl)-1,4,5,6-tetrahydro-2H-benzo[f]quinolin-3-one 
• 148905-81-1 (-)-(4AR)-(10BR)-8-chloro-4-(S-α-methylbenzyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one 
• 148835-24-9 (+)-(4AS)-(10BS)-8-chloro-4-(S-α-methylbenzyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one 
• 113075-47-1 8-chloro-1,4,5,6-tetrahydrobenzo[f]-quinolin-3(2H)-one 
• 152237-49-5 cis-dl-8-bromo-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one 
• 4755-72-0 Chloro-phenyl-acetic acid 

Relevant articles and documents

Method of preventing prostatic cancer development

A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.

Methods for inhibiting bone loss

The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.

Process for preparation of benzo[f]quinolinones

A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5α-reductase and their preparation is disclosed.

The synthesis of (-)-4-methyl-8-chloro-trans-1,23,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one -[3-14C] (LY300502-14C]) via a circuitous route

The synthesis of the C-14 labeled isotopomer of LY300502, a potent 5α-reductase inhibitor has been accomplished in four radiochemical steps. The route involves the synthesis of LY300502-[14C] from LY300502 via a circuitous route; the label was introduced with ethyl chloroformate-[carbonyl-14C]

Benzo (f) quinolinones as 5-alpha-reductase inhibitors

This invention relates to hexa- and octahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5α reductase inhibitors.

Process for the preparation of benzo (F) quinolinones

This invention relates to a process for the preparation of hexa- and octahydrobenzo[f]quinolin-3-ones.

Synthesis of the individual enantiomers of the benzoquinolinone human type 1 steroid 5-α-reductase inhibitors LY191704 and LY266111

The first syntheses of the individual enantiomers of the benzoquinolinone class of selective inhibitors of human Type 1 steroid 5-α-reductase are described. For benzoquinolinones lacking an angular substituent, the approach relies upon an enamine acryloyl